Biological evaluation of heparin octadecasaccharides as iduronate-2-sulphatase inhibitors with chaperone effect

Omar Affandi¹,³, Abdul Rahman Salina¹, Amin Nordin Fatimah Diana¹, Aziz Nur Azian¹, Kamarudin Balqis¹, Mohamad Rosnani¹, Muhamad Nur Jannaim¹, Saat Muhammad Nor Farhan¹, Abdul Jalil Julaina¹, Ahmad Noorden Mohd Shihabuddin³

¹IEM & Genetics Unit, NMCR, Institute for Medical Research, National Institutes of Health, ³Bioassay Unit, HMRC, Institute for Medical Research, National Institutes of Health, ³Faculty of Pharmacy, Universiti Teknologi MARA (UiTM)

ABSTRACT

Introduction: Mucopolysaccharidoses Type II (MPS II) is an X-linked lysosomal storage disorder characterised by IDS mutations leading to iduronate-2-sulphatase (IDS) deficiency and glycosaminoglycan substrate accumulation. Due to the limitations of currently available treatments, pharmacological chaperone (PC) has been suggested as a potential alternative therapy to MPS II. Here, we describe the biological characteristics of heparin octadecasaccharides (HO18) as an IDS inhibitor and the potential of PC in treating the disease.

Methods: The chaperone effect of HO18 was evaluated using recombinant IDS protein for kinetic, inhibition, thermal stability, dose-dependent, and cell viability studies.

Results: A kinetic study through the Lineweaver-Burk plot indicated that HO18 may act as a competitive inhibitor attached to the substrate binding site with the Michaelis-Menten constant (Km) of 1703.67 μM with a Vmax of 1666.67 μmolh⁻¹. The higher affinity of HO18 for IDS was observed at neutral pH (Half maximal inhibitory concentration, IC₅₀=29.5 μM, pH 7.0) compared to acidic (lysosomal) pH (IC₅₀=97.9 μM, pH 5.0) which suggests that it is a potent inhibitor. Furthermore, HO18 significantly improved the stability of IDS at 67°C (p<0.05) as well as increased IDS activity in a dose-dependent manner. In addition, HO18 at the concentration of 18.82 μM reduces cell viability by 50%.

Conclusion: These findings strongly suggest that HO18 could be used as a potential PC for MPS II. Further in vitro studies utilising the expression of IDS-mutated enzymes can be carried out for further validation.